Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EPS (Weighted Average and Diluted) (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with -$0.09 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 80.85% to -$0.09 in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.95, a 182.14% decrease, with the full-year FY2025 number at -$3.95, down 180.14% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.09 for Q4 2025 at Myriad Genetics, up from -$0.29 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.3 in Q3 2021 to a low of -$3.57 in Q2 2025.
  • A 5-year average of -$0.51 and a median of -$0.32 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 112.05% in 2021, then crashed 792.5% in 2025.
  • Myriad Genetics' EPS (Weighted Average and Diluted) stood at -$0.1 in 2021, then plummeted by 420.0% to -$0.52 in 2022, then skyrocketed by 34.62% to -$0.34 in 2023, then crashed by 38.24% to -$0.47 in 2024, then skyrocketed by 80.85% to -$0.09 in 2025.
  • Per Business Quant, the three most recent readings for MYGN's EPS (Weighted Average and Diluted) are -$0.09 (Q4 2025), -$0.29 (Q3 2025), and -$3.57 (Q2 2025).